Veterinary Medicine Information website

CANIGEN L SUSPENSION FOR INJECTION FOR DOGS

Authorised
  • Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
  • Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated
Download as PDF

Product identification

Medicine name:
CANIGEN L SUSPENSION FOR INJECTION FOR DOGS
Active substance:
  • Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
  • Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
    4350.00
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated
    4250.00
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AB01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Germany
Available in:
  • Germany
Package description:
  • Plastic box of 1 vial containing 1 ml of suspension
  • Plastic box of 100 vials containing 1 ml of suspension
  • Plastic box of 50 vials containing 1 ml of suspension
  • Plastic box of 25 vials containing 1 ml of suspension
  • Plastic box of 10 vials containing 1 ml of suspension
  • Cardboard box of 1 vial containing 1 ml of suspension
  • Cardboard box of 100 vials containing 1 ml of suspension
  • Cardboard box of 50 vials containing 1 ml of suspension
  • Cardboard box of 25 vials containing 1 ml of suspension
  • Cardboard box of 10 vials containing 1 ml of suspension

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac
Responsible authority:
  • Paul-Ehrlich-Institut
Authorisation number:
  • PEI.V.11853.01.1
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0310/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

English (PDF)
Published on: 14/03/2026
Download
German (PDF)
Published on: 15/05/2024
Download

eu-puar-frv0310001-mr-rpe293-en.pdf

English (PDF)
Published on: 13/03/2026
Download